Guide
An earlier version of this page compared the cheapest compounded semaglutide with an approved oral tablet at a flat $149. That is the price at 1.5 and 4 mg only. The 9 and 25 mg maintenance doses are $299, and the $149 rate on 4 mg ends on 31 August 2026.
At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not four dollars. We publish this as COR-013 because it is the starter-price error this site documents in others.
The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.
We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.
Is Berberine “Nature’s Ozempic”? What the Trials Actually Show
No. Meta-analyses of berberine report roughly 4 to 5 pounds of weight loss, and some reviews find no significant effect at all. Semaglutide reported 14.9% of body weight
No. Meta-analyses of berberine report roughly 4 to 5 pounds of weight loss, and some reviews find no significant effect at all. Semaglutide reported 14.9% of body weight in STEP-1 and semaglutide 14.9% in STEP-1. They are not comparable, and berberine is not FDA-approved for weight loss.
What does the comparison actually look like?
| Field | Berberine | Semaglutide | Semaglutide |
|---|---|---|---|
| Mean weight loss | ~4–5 lb | 14.9% of body weight | 14.9% of body weight |
| Evidence base | Meta-analyses of small trials; some find no effect | STEP-1, n>1,900 | STEP-1, n>2,500 |
| FDA-approved for weight loss | No | Yes | Yes |
| Mechanism | AMPK activation, hypothesised | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Regulated as | Dietary supplement | Prescription drug | Prescription drug |
For a 200 lb person, 14.9% is roughly 45 lb. The gap is about tenfold, not marginal.
“Nature’s Ozempic” implies a comparable mechanism at a lower price. Berberine does not act on the GLP-1 receptor at all. It is hypothesised to work through AMPK activation, which is a different pathway with a different evidence base.
Because it is sold as a dietary supplement, it is not reviewed for efficacy before sale, and dose and purity vary between products in ways a prescription drug's do not.
Are there interactions worth knowing?
Berberine is reported to affect the CYP450 enzyme system, which metabolises a large share of common medications. It has also been associated with additive effects alongside glucose-lowering drugs. That makes it a conversation with a pharmacist or prescriber rather than an unsupervised purchase, particularly if you take anything for blood pressure, blood sugar or clotting.
If price is why you are looking, what are the real options?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings offer | $25 | $300 | Capped at $100/month in savings |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Approved oral tablet, 1.5 or 4 mg | $149 | — | Captured at source — 4 mg rises to $199 after 31 Aug 2026 |
| Approved oral tablet, 9 or 25 mg maintenance | $299 | $3,588 | Captured at source |
| Compounded, 12-month, flat at every dose | $145 | $1,740 | Captured at source |
| Compounded, month-to-month, flat | $165 | $1,980 | Captured at source |
| Brand Wegovy pen, new-patient intro | $199 | — | First two fills only, to 31 Dec 2026 |
| Brand Wegovy pen, 0.25–2.4 mg | $349 | $4,188 | Captured at source |
| Brand Wegovy HD 7.2 mg | $399 | $4,788 | Captured at source |
| Brand Wegovy, retail list | ~$1,349 | ~$16,188 | Third-party claim |
| Compounded tirzepatide, for comparison | $186 | $2,232 | Captured at source |
Read the dose column. The approved oral tablet is a ladder, not a flat rate: $149 at 1.5 and 4 mg, $299 at 9 and 25 mg. We published it as a flat $149 and corrected that on 4 August 2026 — COR-013. At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not about $154 a month at a maintenance dose.
The honest answer to “is there a cheap alternative that works like a GLP-1” is that the cheapest things that work like a GLP-1 are GLP-1s — $149 for an approved oral, or $145 for the cheapest compounded programme we captured.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is berberine really nature's Ozempic?
No. Meta-analyses report roughly 4 to 5 pounds of weight loss, and some reviews find no significant effect. It does not act on the GLP-1 receptor and is not FDA-approved for weight loss.
How much weight does berberine cause you to lose?
About 4 to 5 pounds in meta-analyses, against 14.9% of body weight for semaglutide in STEP-1.
Is berberine safe to take with other medications?
It is reported to affect the CYP450 enzyme system, which metabolises many common drugs, so it is worth raising with a pharmacist or prescriber rather than starting unsupervised.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- SURMOUNT-3 Tirzepatide Trial ExplainedResearch
- SURMOUNT-1 Tirzepatide Trial ExplainedResearch
- SUMMIT Trial: Tirzepatide and HFpEFResearch
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- Retatrutide Phase 3 Results and How It ComparesResearch
- Evidence and Citation PolicyCore & Trust
- Editorial StandardsCore & Trust
Related coverage
- Authors and Analysts
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List
- Comment Period on the GLP-1 Bulks Proposal Extended to 30 July
- FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products
- FDA Panel Recommends Six of Seven Peptides for Compounding, Overriding Its Own Scientists
- FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week
- We publish two prices that expire on a known date. Until today we did not say so
GLP-1 Semaglutide Rx. “Is Berberine “Nature’s Ozempic”? What the Trials Actually Show.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/berberine-vs-glp1-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.